Nestlé Health Science just funneled an impressive $42.5 million investment into Cambridge-based Pronutria Biosciences – a startup aimed at developing nutrition-based therapeutics for conditions such as amino acid imbalance.
Nestlé first partnered with Pronutria last January, so its new stake in the company isn’t surprising.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The funding will be used to expand Pronutria’s programs in treating muscle, neurological and liver diseases – though it hasn’t disclosed which specific indications it’s after. Pronutria says it’s developing oral biologics – derived from the food proteome – to engineer specific amino acid formulations to correct imbalances found in the disease pathways of some 2,000 conditions.
Funding for the company’s therapeutics Pronutria closed out a $39 million Series C round last May; immediately after a February 2015 B round of $28 million. The company launched in 2010 and has raised more than $100 million to date. Flagship Ventures is the founding investor.
